Visit NavNeuro at:

Episode 19 | Redefining Alzheimer's Disease: Does Cognition Matter? - With Dr. Adam Brickman


The estimated annual cost of healthcare for individuals living with Alzheimer’s disease (AD) or other dementias is almost $300 billion. In addition to this financial burden, the number of adults aged 65 or older is projected to double and it is expected an estimated 10 million of these individuals will develop AD by 2050. Despite global efforts to understand and ultimately assess, diagnose, and treat Alzheimer’s disease (AD) more effectively, a consensus definition of AD still does not exist. In 2018, the National Institute of Aging – Alzheimer’s Association (NIA-AA) Research Framework recommended that we should shift the definition of AD from a syndrome (i.e., the cognitive/behavioral symptoms that individuals present with) to a purely biological construct, specifically the presence of βamyloid deposition, pathologic tau, and neurodegeneration (the “A/T/N” model). In this episode, we talk with Dr. Adam Brickman about the NIA-AA Research Framework biological definition of AD, the role of vascular contributions, assumptions about the amyloid hypothesis, and implications of not including the clinical syndrome in the diagnosis of AD.

apa-logo_white_screenThe International Neuropsychological Society is approved by the American Psychological Association to sponsor continuing education for psychologists. The International Neuropsychological Society maintains responsibility for this program and its content.

Adam Brickman
Instructor Credentials

Adam Brickman, Ph.D., is the Herbert Irving Associate Professor of Neuropsychology in the Department of Neurology at Columbia University, the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, the Gertrude H. Sergievsky Center. Dr. Brickman has published over 200 peer-reviewed manuscripts and received the 2019 Arthur Benton Mid-Career Research Award for his scientific contributions in the field of cognitive aging and Alzheimer’s disease. Specifically, he is interested in white matter abnormalities and the intersection between vascular disease and Alzheimer’s disease. He is also interested in using advanced neuroimaging techniques, traditional neuropsychological tests, and functional assessment to understand how cognitive reserve and cerebrovascular risk factors interact with the aging brain and cognitive abilities.

Dr. Brickman has served as a member of the Aging Systems and Geriatrics Study Section for the National Institutes of Health and as a member of the editorial board of the Journal of the International Neuropsychological Society (JINS) and Neuropsychology Review. He has held several leadership roles, including co-chairing and chairing the Division 40 (Clinical Neuropsychogy) program committee in 2010 and 2011, serving on the Division 40 Scientific Advisory Committee since 2007, and serving as the only neuropsychologist on the APA Committee on Aging.

Topics Covered
  • Biological definition of Alzheimer’s disease (AD) (7:08)
  • A/T/N framework (10:14)
  • Why not separate Alzheimer’s disease amyloid and tau pathology from other diseases like vascular disease and treat it differently? (13:52)
  • Is the definition of AD just an issue of semantics? (19:27)
  • Implications on clinical trials of probable AD (24:54)
  • Funding considerations (29:42)
  • Did amyloid or tau pathology come first? (31:38)
  • Including “c” (cognition) into the A/T/N framework (35:30)
  • ADc vs ADp (38:15)
  • Reducing hypertension reduces risk of stroke. Is that the same as reducing amyloid (amyloid hypothesis)? (40:47)
  • Implications of amyloid disclosure (44:30)
  • Alternatives to the amyloid hypothesis (49:10)
  • AD and dementia: what’s the difference? (52:21)
  • Embracing a biological orientation (55:30)
Educational Objectives
  • List the biological definition of Alzheimer’s disease (AD) and how it differs from previous definitions
  • Discuss the implications of a biological definition of AD on the practice of clinical neuropsychology as well as cognitive neuropsychological research
  • Describe the amyloid hypothesis as well as alternative hypotheses for the development of AD
Target Audience
  • Introductory
  • Date Available: 2019-05-01
  • You may obtain CE for this podcast at any time.
Offered for CE
  • Yes
  • Members $20
  • Non-Members $25
Refund Policy
  • This podcast is not eligible for refunds
CE Credits
  • 1.0 Credit(s)
  • N/A
  • N/A
  • Drachman, D. A. (2014). The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer’s disease. Alzheimer’s & Dementia, 10(3), 372-380.
  • Glymour, M. M., Brickman, A. M., Kivimaki, M., Mayeda, E. R., Chene, G., Dufouil, C., & Manly, J. J. (2018). Will biomarker-based diagnosis of Alzheimer’s disease maximize scientific progress? Evaluating proposed diagnostic criteria. European Journal of Epidemiology, 33, 607-612.
  • Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., et al. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement, 14(4), 535-562.
  • Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., et al. (2016). A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology, 87(5), 539-547.
  • Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., et al. (2013). Tracking pathophysiological processes in Alzheimer’s disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol, 12(2), 207-216.
  • Jack Jr, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., et al. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. The Lancet Neurology, 9(1), 119-128.
  • McCleery, J., Flicker, L., Richard, E., & Quinn, T. J. (2019). When is Alzheimer’s not dementia-Cochrane commentary on The National Institute on Ageing and Alzheimer’s Association Research Framework for Alzheimer’s disease. Age and Ageing, 48, 174-177.
  • Salloway, S. (2018). Improving evaluation of patients with cognitive impairment with amyloid positron emission tomography. JAMA Neurol, 75(9), 1045-1046.
  • Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., et al. (2011). Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & dementia, 7(3), 280-292.